ABSTRACT
A large variation in the severity of disease symptoms is one of the key open questions in COVID-19 pandemics. The fact that only a small subset of people infected with SARS-CoV-2 develop severe disease suggests that there have to be some predisposing factors, but biomarkers that reliably predict disease severity have not been found so far. Since overactivation of the immune system is implicated in a severe form of COVID-19 and the IgG glycosylation is known to be involved in the regulation of different immune processes, we evaluated the association of inter-individual variation in IgG N-glycome composition with the severity of COVID-19. The analysis of 166 severe and 167 mild cases from hospitals in Spain, Italy and Portugal revealed statistically significant differences in the composition of the IgG N-glycome. The most notable difference was the decrease in bisecting N-acetylglucosamine (GlcNAc) in severe patients from all three cohorts. IgG galactosylation was also lower in severe cases in all cohorts, but the difference in galactosylation was not statistically significant after correction for multiple testing. To our knowledge, this is the first study exploring IgG N-glycome variability in COVID-19 severity.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
This was a retrospective study on leftover diagnostic samples
Funding Statement
This work was supported in part by the European Structural and Investment Funds grant for the Croatian National Centre of Competence in Molecular Diagnostics (#KK.01.2.2.03.0006), National Centre of Research Excellence in Personalized Healthcare grant (#KK.01.1.1.01.0010) and by Croatian Science Foundation project #IP CORONA-2020-04. MARBiobanc work was supported by grants from Instituto de Salud Carlos III/FEDER (PT17/0015/0011) and the Xarxa de Bancs de tumors sponsored by Pla Director d'Oncologia de Catalunya (XBTC). Clara Barrios is funded by grants FIS-FEDER-ISCIII PI16/00620 and PERIS STL008. The Institute of Molecular Pathology and Immunology of the University of Porto integrates the Institute for Research and Innovation in Health (i3S) research unit, which is partially supported by the Portuguese Foundation for Science and Technology (FCT). This article was funded by the FCT, in collaboration with the Portuguese Agency for Clinical Research and Biomedical Innovation (AICIB) under the special funding, RESEARCH 4 COVID-19 Project #006 granted to the PI Salome S. Pinho. This article is also a result of the project NORTE-01-0145-FEDER-000029, supported by the Norte Portugal Regional Programme (NORTE 2020) under the PORTUGAL 2020 Partnership Agreement through the European Regional Development Fund. This work was also funded by Fundo Europeu de Desenvolvimento Regional (FEDER) funds through the COMPETE2020-Operacional Programme for Competitiveness and Internationalization (POCI), Portugal 2020, and by Portuguese funds through the FCT in the framework of the project (POCI-01-0145-FEDER-028772). IA [SFRH/BD/128874/2017] and MV [PD/BD/135452/2017] received funding from the FCT.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Biological samples were obtained from hospitals in Spain, Italy, and Portugal. The study protocol conformed to the ethical guidelines of the 1975 Declaration of Helsinki and the study was approved by ethical committees of ASST Papa Giovanni XXIII Hospital in Bergamo, Hospital del Mar in Barcelona and by the institutional ethics committee of Centro Hospitalar Universitario do Porto (CHUP), Centro Hospitalar de Vila Nova de Gaia/Espinho (CHVNG) and Hospital Beatriz Angelo (HBA), Loures, Lisbon. All participants gave informed consent.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data is available from corresponding authors
Abbreviations
- 2-AB
- 2-aminobenzamide
- B
- percentage of glycans with bisecting
- GlcNAcBEH
- ethylene-bridged siloxane
- CFR
- case fatality rates
- DMSO
- dimethylsulfoxide
- F
- percentage of fucosylated glycans
- G0
- percentage of glycans without galactose
- G1
- percentage of glycans with one galactose
- G2
- percentage of glycans with two galactoses
- GlcNAc
- N-acetlyglucosamine
- HILIC
- hydrophilic interaction liquid chromatography
- IgG
- immunoglobulin G
- PEEK
- polyether ether ketone
- S
- percentage of all glycans with sialic acid
- SPE
- solid-phase extraction
- UHPLC
- ultra-high-performance liquid chromatography
